Bringing The Next-Generation Of Antibiotics
to win the war against resistant bacteria
Our Vision
Our company
Omnix Medical is a biopharmaceutical company
Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Our technology
Our exceptional technology offers a first-in-its-class drug
Company News
EUROPE’S ANTIBIOTIC INVESTMENTS STAGNATE AS RESISTANCE CRISIS LOOMS
By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and
OMNIX MEDICAL RECEIVES NIH GRANT FOR THE DEVELOPMENT OF ITS NOVEL ANTIMICROBIAL PEPTIDE OMN6
Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical
OMN6 A NOVEL BIOENGINEERED PEPTIDE FOR THE TREATMENT OF MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA
New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we